Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Kristina Wallenius"'
Autor:
Stefano Bartesaghi, Kristina Wallenius, Daniel Hovdal, Mathias Liljeblad, Simonetta Wallin, Niek Dekker, Louise Barlind, Nigel Davies, Frank Seeliger, Maria Sörhede Winzell, Sima Patel, Matt Theisen, Luis Brito, Nils Bergenhem, Shalini Andersson, Xiao-Rong Peng
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 28, Iss , Pp 500-513 (2022)
Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration
Externí odkaz:
https://doaj.org/article/870f12a5c5cf429dbef9b12f15e31262
Autor:
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang, Patrick CN Rensen
Publikováno v:
eLife, Vol 12 (2023)
Analogues of the hepatokine fibroblast growth factor 21 (FGF21) are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unrav
Externí odkaz:
https://doaj.org/article/10b3762987d94deeac6dedce6336b7ac
Autor:
Kristina Wallenius, Tobias Kroon, Therese Hagstedt, Lars Löfgren, Maria Sörhede-Winzell, Jeremie Boucher, Daniel Lindén, Nicholas D. Oakes
Publikováno v:
Journal of Lipid Research, Vol 63, Iss 3, Pp 100176- (2022)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to increase ketone bodies in patients with type 2 diabetes; however, the underlying mechanisms have not been fully elucidated. Here we examined the effect of the SGLT2 inhibitor dapagl
Externí odkaz:
https://doaj.org/article/776ec5390e114d3cb999d3075c5b5a12
Autor:
Se-Hyung Park, Robert N. Helsley, Leila Noetzli, Ho-Chou Tu, Kristina Wallenius, Gavin O’Mahony, Jeremie Boucher, Jianming Liu, Samir Softic
Publikováno v:
STAR Protocols, Vol 2, Iss 3, Pp 100731- (2021)
Summary: Ketohexokinase (KHK) catalyzes the first step of fructose metabolism. Inhibitors of KHK enzymatic activity are being evaluated in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD) and diabetes. Here, we present a
Externí odkaz:
https://doaj.org/article/8ad1dc90a7ee458c9814f80a26cdf195
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e113328 (2014)
The current study extends previously reported PPARα agonist WY 14,643 (30 µmol/kg/day for 4 weeks) effects on circulating amino acid concentrations in rats fed a 48% saturated fat diet. Steady-state tracer experiments were used to examine in vivo k
Externí odkaz:
https://doaj.org/article/3d0041d436854e26bbf080bff08e6a53
Publikováno v:
PPAR Research, Vol 2013 (2013)
Metabolic flexibility was assessed in male Zucker rats: lean controls, obese controls, and obese rats treated with the dual peroxisome proliferator activated receptor (PPAR) agonist, tesaglitazar, 3 μmol/kg/day for 3 weeks. Whole body glucose dispos
Externí odkaz:
https://doaj.org/article/03c5c3693cd0466eb67c38b5f264b3f4
Autor:
Christine Isaksson, Johan Gabrielsson, Kristina Wallenius, Lambertus A. Peletier, Helena Toreson
Publikováno v:
Dose-Response, Vol 7 (2009)
The objective of this investigation was to use a pharmacokinetic (PK)/pharmacodynamic (PD) approach to describe and evaluate a PK model of nicotinic acid (NiAc) in guinea pigs and a PD feedback model of changes in non-esterified fatty acid (NEFA) con
Externí odkaz:
https://doaj.org/article/41089666acdd48199cec7000fb240dba
Autor:
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang, Patrick CN Rensen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b99d425453df9a925aa60e01e5fc280
https://doi.org/10.7554/elife.83075.sa2
https://doi.org/10.7554/elife.83075.sa2
Autor:
Tobias Kroon, Therese Hagstedt, Ida Alexandersson, Annett Ferm, Marie Petersson, Stefanie Maurer, Bader Zarrouki, Kristina Wallenius, Nicholas D. Oakes, Jeremie Boucher
Publikováno v:
Science Translational Medicine. 14
Circadian rhythms play a critical role in regulating metabolism, including daily cycles of feeding/fasting. Glucokinase (GCK) is central for whole-body glucose homeostasis and oscillates according to a circadian clock. GCK activators (GKAs) effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f2be213f5ef52c8b336fb7df9ac882d
https://doi.org/10.1126/scitranslmed.abh1316
https://doi.org/10.1126/scitranslmed.abh1316
Autor:
Cong Liu, Milena Schönke, Borah Spoorenberg, Joost M Lambooij, Hendrik JP van der Zande, Enchen Zhou, Maarten E Tushuizen, Anne-Christine Andreasson, Andrew Park, Stephanie Oldham, Martin Uhrbom, Ingela Ahlstedt, Yasuhiro Ikeda, Kristina Wallenius, Xiao-Rong Peng, Bruno Guigas, Mariëtte R Boon, Yanan Wang, Patrick CN Rensen
Analogues of the hepatokine FGF21 are in clinical development for type 2 diabetes and nonalcoholic steatohepatitis (NASH) treatment. Although their glucose-lowering and insulin-sensitizing effects have been largely unraveled, the mechanisms by which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e6766169da40861a1df700705827a6
https://doi.org/10.1101/2022.09.20.508654
https://doi.org/10.1101/2022.09.20.508654